Humoral immune response to MUC1 and to the Thomsen-Friedenreich (TF) glycotope in patients with gastric cancer: Relation to survival

References

• Price MR, Rye PD, Hudecz F, O'Sullivan C, Baldwin RW, Edwards PM, et al. Immunological and structural features of the protein core of human polymorphic epithelial mucin. Molec Immunol 1990; 27: 795–802
   PubMed Web of Science ®Google Scholar
• Von Mensdorff-Pouilly S, Snijdewint FGM, Verstraeten AA, Verheijen RHM, Kenemans P. Human MUC1 mucin: A multifaceted glycoprotein. J Biol Markers 2000a; 15: 343–56
   PubMed Web of Science ®Google Scholar
• Taylor-Papadimitriou J, Burchell J, Miles DW, Dalziel M. MUC1 and cancer. Biochim Biophys Acta 1999; 1455: 301–13
   PubMed Web of Science ®Google Scholar
• Hilkens J, Wesseling J, Vos HL, Storm J, Boer B, van der Valk SW, et al. Involvement of the cell-surface bound mucin, episialin/MUC1, in progression of human carcinomas. Biochem Soc Transact 1995; 23: 822–6
   PubMedGoogle Scholar
• Denda-Nagai K, Irimura T. MUC1 in carcinoma host interactions. Glycoconj J 2000; 17: 649–58
   PubMedGoogle Scholar
• Lee HS, Lee HK, Kim HS, Yang HK, Kim YI, Kim WH. MUC1, MUC2, Muc5AC, and MUC6 expressions in gastric carcinomas: Their role as prognostic indicators. Cancer 2001; 92: 1427–34
   PubMedGoogle Scholar
• Baldus SE, Hanisch FG, Monaca E, Karsten UR, Zirbes TK, Thiele J, et al. Immunoreactivity of Thomsen-Friedenreich (TF) antigen in human neoplasms: The importance of carrier-specific glycotope expression on MUC1. Histol Histopathl 1999; 14: 1153–6
   PubMedGoogle Scholar
• Kotera Y, Fontenot JD, Pecher G, Metzgar RS, Finn OJ. Humoral immune immunity against a tandem repeat of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 1994; 54: 2856–60
   PubMed Web of Science ®Google Scholar
• Richards ER, Devine PL, Quin RJ, Fontenot JD, Ward BG, McGuckin MA. Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women. Cancer Immunol Immunother 1998; 46: 245–52
   PubMed Web of Science ®Google Scholar
• Von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, Snijdewint FGM, Kok A, van Kamp GJ, et al. Survival in early breast cancer patients is favourably influenced by a natural humoral immune response to polymorphic epitheliual mucin (MUC1). J Clin Oncol 2000b; 18: 574–83
   PubMed Web of Science ®Google Scholar
• von Mensdorff-Pouilly S, Petrakou E, Kenemans P, Van Uffelen K, Verstraeten AA, Snijdewint FGM, et al. Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and N-acetylgalactosamine (GalNAc) peptides. Int J Cancer 2000; 86: 702–12
   PubMed Web of Science ®Google Scholar
• Hirasawa Y, Kohno N, Yokoyama A, Kondo K, Hiwada K, Miyake M. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Resp Crit Care Med 2000; 161: 589–94
   PubMed Web of Science ®Google Scholar
• Schuman J, Campbell AP, Koganty RR, Longenecker BM. Probing the conformational and dynamical effects of O-glycosylation within the immunodominant region of a MUC1 peptide tumor antigen. J Pept Res 2003; 61: 91–108
   PubMedGoogle Scholar
• Springer GF. T and Tn, general carcinoma autoantigens. Science 1984; 224: 1198–206
   PubMed Web of Science ®Google Scholar
• Kurtenkov O, Miljukhina L, Smorodin J, Klaamas K, Bovin N, Ellamaa M, Chuzmarov V. Natural IgM and IgG antibodies to Thomsen-Friedenreich(T) antigen in serum of patients with gastric cancer and blood donors. Acta Oncol 1999; 38: 939–43
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, Sandrin MS, McKenzie IF. Mimics and cross reactions of relevance to tumour immunotherapy. Vaccine 1999; 18: 268–75
   PubMedGoogle Scholar
• Luo P, Canziani G, Cunto-Amesty G, Kieber-Emmons T. A molecular basis for functional peptide mimicry of a carbohydrate antigen. J Biol Chem 2000; 275: 16146–54
   PubMedGoogle Scholar
• Petelskaya EN, Glinsky VV, Glinsky GV, Deutscher SL, Quinn TP. Characterization of peptides that bind the tumor-associated Thomsen-Friedenreich antigen selected from bacteriophage display libraries. J Mol Biol 1997; 270: 374–84
   PubMedGoogle Scholar
• Galili U, LaTemple DC, Radic MZ. The natural anti-Gal antibody. Subcellular Biochemistry 1999; 32: 79–106
   PubMedGoogle Scholar
• Lauren P. The two histological main types of gastric carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64: 31–49
   PubMedGoogle Scholar
• Von Mensdorff-Pouilly S, Gourevitch MM, Kenemans P, Verstraeten AA, van Kamp GJ, Uffelen K, et al. An enzyme-linked immunosorbent assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUC1). Tumor Biol 1998; 19: 186–95
   PubMed Web of Science ®Google Scholar
• Kurtenkov O, Klaamas K, Miljukhina L. The lower level of natural anti-Thomsen-Friedenreich antigen (TFA) agglutinins in sera of patients with gastric cancer related to ABO(H) blood.group phenotype. Int J Cancer 1995; 60: 781–5
   PubMed Web of Science ®Google Scholar
• Lacroix-Desmazes S, Mouthon L, Kaveri SV, Kazatchkine MD, Weksler ME. Stability of natural self-reactive antibody repertoires during aging. J Clin Immunol 1999; 19: 26–34
   PubMed Web of Science ®Google Scholar
• Santos-Silva F, Fonseca A, Caffrey T, Carvalho F, Mesquita P, Reis C, et al. Thomsen-Friedenreich antigen expression in gastric carcinomas is associated with MUC1 mucin VNTR polymorphism. Glycobiology 2005; 15: 511–7
   PubMedGoogle Scholar
• Karsten U, Serttas N, Paulsen H, Danielczyk A, Goletz S. Binding patterns of DSTR-specific antibodies reveal a glycosylation-conditioned tumor-specific epitope of the epithelial mucin (MUC1). Glycobiology 2004; 14: 681–92
   PubMed Web of Science ®Google Scholar
• von Mensdorf-Pouilly S, Kinarsky L, Engelmann K, Baldus SE, Verheijen RH, Hollingsworth MA, et al. Sequence variant repeats of MUC1 show higher conformational flexibility, are less densely O-glycosylated and induce differencial B lymphocyte response. Glycobiology 2005; 15: 735–46
   PubMedGoogle Scholar